Users of combination oral contraceptives have been reported to be at decreased risk of endometrial cancer in 4 recent case-control studies (Kaufman et al., 1980; Weiss & Sayvetz, 1980; Hulka et al., 1982; Kelsey et al., 1982) . It is not obvious how combination oral contraceptive use may "interact" with other endometrial cancer risk factors: in the above studies the numbers of ever-users of combination oral contraceptives were small, and the possible modifying effects of other risk factors were not (and probably could not be) discussed in any detail.
We report here the results of a case-control study of 127 endometrial cancer patients aged 45 years or less at diagnosis. By restricting attention to these young women we hoped to obtain a sufficient number of oral contraceptive users that the possible interaction with other risk factors could be evaluated.
Methods
The cases were white women with microscopically confirmed adenocarcinoma of the endometrium (excluding carcinoma in situ) first diagnosed between January 1972 and December 1979. Any such woman, unless she had a Spanish surname and was born outside the United States, was eligible for inclusion if she was 45 years of age or less at diagnosis with no prior malignancies, was still alive Correspondence: M.C. Pike Received 5 December 1982; accepted 18 February 1983. and in the opinion of her physician was able to be interviewed, and was a resident of Los Angeles County at the time of her diagnosis. The cases were identified by the University of Southern California Cancer Surveillance Program (CSP), the population based cancer registry for Los Angeles County (Mack, 1977) .
The CSP identified 185 such cases; 36 of these women refused to be interviewed. We obtained completed questionnaires on 149 (81%).
We sought one individually-matched control for each of these 149 cases. The control had. to be white (excluding foreign-born if with a Spanish surname), have a birth date within 5 years of her matched case, have no prior malignancies, and have an intact uterus on her "pseudo-diagnosis" date (defined below). She also had to be at least as old at interview as her matched case was at diagnosis.
The controls were obtained by a procedure that defines a sequence of houses on specified neighbourhood blocks in the area where the matched case resided at the time of her diagnosis. Our goal was to interview the first matching female resident in the sequence. If no one was home at the time of visit, we left an explanatory letter and made 3 further follow-up visits some days later. In 110 instances, the first appropriate person agreed to participate. The second matched control cooperated in 14 instances, the third match in 2 instances, and the fourth match in 6 instances. For (Delforge & Ferin, 1970) , and the relative potencies of the 5 gestagens is 1, 1.09, 2, 15 and 30 respectively (Greenblatt, 1967) . A potency ratio (E/G ratio) may be calculated (Mishell, 1979) for each preparation as (oestrogen component in mcg x relative potency) dividend by (gestagen component in mg x relative potency). The E/G ratio of the commonly-used preparations varies from 6.7 for Demulen to 175 for Ovcon-35 (Mishell, 1979 Multivariate regression methods for individually matched case-control studies were used for statistical analysis (Breslow et al., 1978; Holford et al., 1978; Smith et al., 1981; Thomas, 1981) . The odds ratios estimated from such analyses closely approximate the related relative risks and the latter term is used in the text for clarity of presentation.
Results
Eleven of the patients were aged < 30 years at diagnosis, 49 were aged 31-40, and 67 were aged 41-45. The socio-economic class of the patients and their individually-matched controls were very similar, as would be expected from the method of choosing controls by neighbourhood.
The relative risk (RR) for endometrial cancer was increased by long-term use of sequential oral contraceptives (SOCs) ( Table I) : 10 women had used SOCs for .2 years, 9 of these women were cases. Five of the 9 cases with long-term SOC use had used C-Quens, 4 had used Oracon, and 1 each had used Norquens and Ortho-Novum SQ. As expected, oestrogen replacement therapy (ERT) was associated with increased risk (Table I) , although the result was not statistically significant. One may conclude from these results and other published series (Lyon, 1975; Smith et al., 1975; Ziel et al., 1975; Mack et al., 1976; McDonald et al., 1977; Kelsey et al., 1982 ) that long-term (.2 years) SOC or ERT use was the cause of the endometrial cancer in most of the long-term SOC or ERT users. For this reason we excluded from all further analyses those case-control pairs in which either case or control used SOC or ERT for >2 years, leaving 110 case-control pairs (in 1 case-control pair both case and control had used SOC for >2 years). §Estimated odds ratio at 3 years. Actual "matched" observed odds ratio is infinity, as the single control was matched to a case who took sequentials for more than 2 years.
The RR for endometrial cancer was significantly decreased by increasing numbers of full-term (.28 weeks) pregnancies (FTPs) (Table II) : a woman who had had . 4 FTPs had only 6% the risk of a nulliparous woman. Incomplete pregnancies (spontaneous and induced abortions) were associated with a slight decrease in risk (data not shown) 5.6 incomplete pregnancies was estimated (Table II) . Recent COC use (i.e. use within 1 year of the diagnosis date) was positively associated with duration of COC use. However, there was no effect of recency of COC use over and above the effect explicable by this association with duration of COC use. Table III shows that use of COCs with either "High" or "Low" oestrogen to (Table II) . Quetelet's index (weight/height2) was also significantly positively related to the risk of endometrial cancer. In this data, weight and Quetelet's index were very highly correlated, so that neither relationship with endometrial cancer risk was significant after allowance was made for the other, and Quetelet's index was slightly less discriminatory than weight alone. We have therefore presented only the results for weight.
Weight at age 18 was strongly associated with risk of endometrial cancer (see second last line in Table IV ). The effect could, however, be almost completely "explained" by current weight (see last line in Table IV ), so that weight at age 18 does not add much further information if current weight is known. The RR associated with current weight was only slightly modified by knowledge of weight at age 18. Five cases but no controls had been diagnosed as having diabetes. The cases weighed 185, 195, 200, 225 and 250lbs so that the increased risk 'cannot be distinguished from that due to weight alone.
Long-term infertility, defined as a "recognised" inability to get pregnant for . 3 years, was (Table II) . Infertility of shorter duration was not associated with an increased risk; and there was no further increase in risk with recognised infertility of longer duration. Amenorrhea "requiring" a physician visit was associated with a 5.3-fold increased risk of endometrial cancer (Table II) . Table V shows the maximum likelihood estimates of the logistic parameters (log RRs) for each of the 5 risk factors in Table II fitted singly. All were statistically significant. The Table also shows the estimated parameters and associated significance levels when the 5 factors were fitted together. Only FTPs, current weight and amenorrhea remained statistically significant at the conventional 1-sided 5% level. TFor linear trend in logistic model to actual weight. are all consistent with those shown for all women in Table II. Table VIII shows the multivariate analysis for the 3 statistically significant risk factors (FTPs, COC and infertility): only numbers of FTPs remained statistically significant when the factors were considered jointly. One FTP was the equivalent of -5 years of COC use (0.41/0.080). The reason for the disappearance of infertility as a risk factor was that 50% (10/20) of the infertile cases were nulliparous, while only 18% (2/11) of such controls were nulliparous. There was no effect of age at menarche or age at establishment of regular cycles (or duration of time from menarche to establishment of regular cycles) on the risk of endometrial cancer.
There was no evidence of any increased risk associated with intra-uterine contraceptive devices.
The stage of the endometrial cancer at diagnosis could be determined fromp the CSP records in 72/110 cases. Forty-three had strictly localised disease (local) and 29 had tumour extension at least into the distal two thirds of the myometrium (invasive). The above risk factors were clearly evident for both groups, but the number of invasive cases was not sufficient to be sure that the magnitudes of the effects were the same. One case and 1 control reported that they had been diagnosed with polycystic ovarian disease (PCO) before the diagnosis date. Three additional cases were found to have PCO at the time of diagnosis. The PCO cases weighed 130, 175, 200 and 220lbs, and all were infertile.
Five cases, but only 1 control, reported endometrial cancer in a first degree relative (cases-2 mothers and 3 sisters; controls-1 mother). An additional 5 cases and 1 control reported cancer of the cervix in a first degree relative; some of these may actually have been carcinomas of the endometrium. Breast cancer in a first degree relative was reported by 4 cases and 7 controls.
Discussion
The present case-control study of young white women in the Los Angeles area shows clearly that long-term use of sequential oral contraceptives (SOCs) increases the risk of endometrial cancer. SOCs were removed from sale in 1976 because of case reports of endometrial cancer in SOC users (Lyon, 1975) , and data suggesting that among young endometrial cancer cases who took oral contraceptives the proportion taking SOCs was disproportionately high (Silverberg & Makowski, 1975) . The oestrogenic component of Oracon is 0.1 mg ethinyl oestradiol while the oestrogenic components of the other SOCs is 0.08 mg mestranol; mestranol has only half the oestrogenic potency of ethinyl oestradiol (Greenblatt, 1960) . This suggests that Oracon may be more strongly related to endometrial cancer. In the study of Weiss & Sayvetz (1980) the increased risk of SOCs appeared to be restricted to Oracon users, but we found no evidence of an especially raised risk with this formulation (SOC users: Oracon-6 cases and 3 controls; C-Quens-5 cases and 3 controls; other formulations-2 cases and 1 control). We do not have enough data to settle this question. Only 3/9 long-term SOC cases used SOCs within 6 months of their date of diagnosis, and it therefore appears that the increased risk is not restricted to current users.
Although the increased risk associated with oestrogen replacement therapy (ERT) was not statistically significant, the magnitude of the observed risk was compatible with that found in many studies of post-menopausal endometrial cancer cases (Smith et al., 1975; Ziel et al., 1975; Mack et al., 1976; McDonald et al., 1977; .
We eliminated from all further analyses the 17 case-control pairs in which either the case or the control had used SOCs or ERT for .2 years. We did this in order to simplify the presentation and so that we did not need to build these 2 variables into all calculations of relative risks for other factors. The usual straightforward "adjustment" using logistic methods assumes that the relative risks of different factors is multiplicative and we saw no reason to assume this for the sake of retaining these 17 pairs.
The present study provides clear evidence that the risk of endometrial cancer in young women is markedly increased by obesity. It is well known that obesity is a major risk factor for endometrial cancer in post-menopausal women (Damon, 1960; Wynder et al., 1966; Elwood et al., 1977; Kelsey et al., 1982; La Vecchia et al., 1982) , and case reports have suggested that young endometrial cancer cases tend to be very obese (Sommers et al., 1949; Dockerty et al., 1951; Peterson, 1968) . In our population 50% (55/110) of the cases weighed 2150lbs, and the associated attributable risk percent (ARP) is 38%, i.e. 38% of the current cases of endometrial cancer in Los Angeles County in young women are attributable to obesity, defined as weighing . 150 lbs.
Obesity is thus now clearly established as an extremely important (and presumably preventable) cause of endometrial cancer both in pre-menopausal and post-menopausal women. Table VI shows that if the obesity is associated with infertility or amenorrhea the risk of endometrial cancer is particularly high.
This study shows that the risk of endometrial cancer in young women is reduced considerably by increasing numbers of FTPs. This is consistent with the results of studies of older mainly postmenopausal women (Damon, 1960; Wynder et al., 1966; Elwood et al., 1977; Kelsey et al., 1982; La Vecchia et al., 1982) . Incomplete pregnancies also appear to be protective. The extent of protection afforded by an incomplete pregnancy relative to that afforded by a FTP is roughly in proportion to the length of the pregnancy. The decreased risk associated with FTPs was not due to any relationship between weight and numbers of FTPs. The results shown in Tables II and VII suggest a larger protective effect from first than from subsequent pregnancies. Although analysis showed that this effect was not statistically significant, such an effect should be looked for in future studies.
Although the current study has only 1 less endometrial cancer case who had ever used COCs than all other studies combined (Kaufman et al., 1980; Weiss & Sayvetz, 1980; Hulka et al., 1982; Kelsey et al., 1982) , we still have too little data to be able to accurately estimate the protective effect of COC use or to confidently delineate the group of women for whom it is protective. We saw in Table  VI that COC use does not appear to be protective in obese women, and the decreased risk in nonobese women is not statistically significant when considered together with numbers of FTPs. Inspection of the data (not shown) suggests that the reason for the latter reduction in effect is that COC use does not appear to be protective in women with >3 FTPs. Further study of large numbers of young endometrial cancer cases is needed to settle these issues.
The greatly increased risk associated with obesity in post-menopausal women has been interpreted in "excess" oestrogen terms by a number of authors (Siiteri, 1978; Nisker et al., 1980; Henderson et al., 1982) . Plasma oestrogen in the post-menopausal woman is largely derived by extra-glandular conversion of androstenedione to oestrone, and the rate of this aromatization increases with body weight since adipose tissue is particularly rich in the necessary enzymes (Siiteri & MacDonald, 1973) . Oestradiol is then derived from peripheral conversion of oestrone (Vermeulen & Verdonck, 1978) . The bio-availability of oestradiol may be related to the concentration of sex-hormone-binding globulin (SHBG) in the serum, and recent results show that the SHBG concentration is lower in obese women (Nisker et al., 1980) . Thus, obese women not only have greater concentrations of circulating oestrogens, but the oestradiol may be more available to oestrogen-responsive tissue.
Progesterone and other gestagens have profound effects on the endometrium and are therapeutically useful in treating both endometrial hyperplasia and carcinoma. Gestagens increase the activity of the dehydrogenase that converts oestradiol to the biologically less active oestrone (Tseng & Gurpide, 1976) ; and gestagens decrease the concentration of oestradiol receptors (Hsueh et al., 1975) . Maximum mitotic activity in the endometrium occurs in the follicular phase of the cycle, and gestagens cause differentiation of the endometrial cells to a secretory state (Novak & Woodruff, 1979) .
The "unopposed oestrogen hypothesis" for endometrial cancer joins these two factors together (Siiteri, 1978; Nisker et al., 1980; Henderson et al., 1982) . Our results showing the especially increased rate of endometrial cancer in obese women with amenorrhea provide very strong support for this hypothesis. Increased fertility may protect against endometrial cancer directly-the state of the endometrium during pregnancy being very similar to its state during the luteal phase of the cycle with little mitotic activity. Part of the protection from increased parity may, however, be indirect-high parity may imply a low frequency of anovular cycles in which little or no progesterone is produced.
Protection from long-term COC use also supports the unopposed oestrogen hypothesis-the gestagen component of COCs normally being sufficiently potent to prevent proliferation of the endometrium (Anderson, 1979) . The dose of gestagen may, however, not be sufficiently strong to inhibit endometrial proliferation in very obese women; this would explain our failure to find a protective effect of COC use in such women. We have not been able to find information about the state of the endometrium in very obese women on COCs.
Although there was no overall effect of age at menarche or duration of time from menarche to establishment of regular cycles on endometrial cancer risk, these negative results appeared to be due to essentially contradictory results in different weight categories of cases. Relative to controls the obese cases tended to have early menarche and long duration to establishment of regular cycles, while the non-obese cases tended to have late menarche and short duration to establishment of regular cycles. None of these results were, however, statistically significant and a large study will be neede to shed light on this question.
